CA-PIVOTAL
18.8.2015 21:52:16 CEST | Business Wire | Pressemeddelelse
Pivotal announced today their board of directors has appointed Rob Mee as Chief Executive Officer. Rob Mee recently served as Pivotal’s Executive Vice President of Products and Research & Development. As CEO, Rob Mee succeeds Paul Maritz, who will remain with Pivotal and serve on Pivotal’s board of directors in the newly created position of Executive Chairman.
“Rob Mee has been credited for shaping the software development cultures of some of Silicon Valley’s most influential and valuable companies. He's an exceptional leader and technologist, passionate about our mission, committed to our principles and values, and knows how to build a successful business,” said Paul Maritz, Pivotal’s Executive Chairman. “As Executive Chairman, I look forward to remaining actively engaged with Pivotal, its partners and its customers, and supporting Rob in his new role as CEO.”
Pivotal’s CEO Rob Mee said, “I am honored and excited to lead Pivotal in our mission to transform how the world builds software. Paul has been instrumental in realizing the vision of Pivotal and we will be forever grateful for his long-sighted leadership – he has left an indelible legacy and will continue to be an invaluable resource as our Executive Chairman.”
Pivotal®, the company accelerating digital transformation for enterprises, also announced Pivotal Cloud Foundry®, Pivotal’s cloud native platform, reached a financial milestone by crossing $100 million in annual bookings run-rate.
“Pivotal has an extraordinary opportunity to deliver differentiated value to the world’s most valuable brands by providing an open and open-source cloud platform in Pivotal Cloud Foundry which is designed to support the development and deployment of modern, cloud-oriented applications and have them run on multiple clouds, private or public,” said Paul Maritz. “Crossing the $100 million dollar milestone is a great sign that Pivotal Cloud Foundry is being embraced by customers and partners and is emerging as the leading open cloud platform.”
Rob Mee said, “Entire industries, from automotive to financial services to retail, are being disrupted. Pivotal brings a transformative approach to software development to help companies thrive in a disruptive world.”
Resources
- Pivotal Blog Paul Maritz “How Far We’ve Come”
- Pivotal Blog Rob Mee “We Transform How The World Builds Software”
About Pivotal
Pivotal is a trusted partner for IT innovation and digital transformation, enabling enterprises to provide modern software-driven experiences for their customers and workforces. The combination of leading agile development services, an open cloud platform and open suite of big data products accelerate innovation cycles for our customers across every industry. More at www.pivotal.io
©2015 Pivotal Software, Inc. All rights reserved. Pivotal and Pivotal Cloud Foundry are trademarks and/or registered trademarks of Pivotal Software, Inc. in the United States and/or other countries.
This release contains “forward-looking statements” as defined under the Federal Securities Laws. Actual results could differ materially from those projected in the forward-looking statements as a result of certain risk factors, including but not limited to: (i) adverse changes in general economic or market conditions; (ii) delays or reductions in information technology spending; (iii) risks associated with managing the growth of Pivotal’s business; (iv) competitive factors, including but not limited to pricing pressures and new product introductions; (v) Pivotal’s customers' ability to transition to new products and computing strategies such as cloud computing, the uncertainty of customer acceptance of emerging technologies, and rapid technological and market changes; (vi) changes to product development timelines; (vii) Pivotal's ability to protect its proprietary technology; (viii) Pivotal's ability to attract and retain highly qualified employees; and (ix) risks related to data and information security vulnerabilities. These forward looking statements are based on current expectations and are subject to uncertainties and changes in condition, significance, value and effect as well as other risks disclosed previously and from time to time in documents filed by EMC Corporation, the parent company of Pivotal, with the U.S. Securities and Exchange Commission. EMC and Pivotal assume no obligation to, and do not currently intend to, update any such forward-looking statements after the date of this press release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150818006491/en/
Contact:
Pivotal
Media Relations
Michael Lee
mlee@pivotal.io
Analyst
Relations
Avi Orenstein, +1-925-998-4582
aorenstein@pivotal.io
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum